Jorge Filmus and Mariana Capurro Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma The FEBS Journal 280
Glypican-3 (GPC3) is expressed by most hepatocellular carcinomas (HCCs), but it is not detected in normal liver or benign liver disease. Consequently, immunostaining of liver biopsies for GPC3 is currently being used by clinical pathologists to confirm HCC diagnosis. Two therapeutic approaches for HCC that target GPC3 are currently being tested in phase II clinical trials.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf